(Q37425658)

20 August 2017

1 reference

title

Cytochrome P450 metabolism and inhibition: analysis for drug discovery (English)

1 reference

20 August 2017

1 reference

Barry C Jones

1

1 reference

20 August 2017

Donald S Middleton

series ordinal

2

1 reference

20 August 2017

Kuresh Youdim

series ordinal

3

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Progress in medicinal chemistry

20 August 2017

published in

1 reference

20 August 2017

volume

47

1 reference

20 August 2017

page(s)

239-263

1 reference

Human hepatic cell cultures: in vitro and in vivo drug metabolism

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Cytochromes P450 and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Coordinated induction of drug transporters and phase I and II metabolism in human liver slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Cryopreservation of hepatocytes: a review of current methods for banking.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Enzyme source effects on CYP2C9 kinetics and inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Enzyme kinetics of cytochrome P450-mediated reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

High throughput P450 inhibition screens in early drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Fluorometric screening for metabolism-based drug--drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Validated assays for human cytochrome P450 activities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

In vitro approaches to investigate mechanism-based inactivation of CYP enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Time-dependent CYP inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Development of a combined protein and pharmacophore model for cytochrome P450 2C9.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Crystal structure of human cytochrome P450 2C9 with bound warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Synthetic strategies to lower affinity for CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Crystal structure of human cytochrome P450 2D6

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Heterotropic cooperativity in oxidation mediated by cytochrome p450.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Structural basis for ligand promiscuity in cytochrome P450 3A4.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Involvement of human liver cytochrome P4502B6 in the metabolism of propofol

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Molecular characterization of CYP2B6 substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17beta-glucuronide oxidation to 2-hydroxy-estradiol-17beta-glucuronide by CYP 2C8.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

Drug-drug interactions: an important negative attribute in drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2900206-3

7 January 2021

10.1016/S0079-6468(08)00206-3

Identifiers

DOI

1 reference

20 August 2017

1 reference